You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 48 No. 1, January 1991 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Changes in Plasma Homovanillic Acid Concentrations in Schizophrenic Patients Following Neuroleptic Discontinuation

Michael Davidson, MD; Renë S. Kahn, MD; Peter Powchik, MD; Patricia Warne, PhD; Miklos F. Losonczy, MD, PhD; Rami Kaminsky, MD; Seth Apter, MA; Stacey Jaff; Kenneth L. Davis, MD

Arch Gen Psychiatry. 1991;48(1):73-76.


Abstract

• Changes in plasma levels of the dopamine metabolite homovanillic acid have been reported to correlate with changes in the severity of schizophrenic symptoms during neuroleptic administration and after neuroleptic discontinuation. This study examined the effects of discontinuation of neuroleptic treatment on plasma homovanillic acid levels in 23 patients with chronic schizophrenia. It was hypothesized that clinical decompensation would be associated with increased plasma homovanillic acid levels. Plasma homovanillic acid was measured during administration of neuroleptic medication and during a subsequent 6-week drug-free period. Nine patients decompensated during the drug-free period and 14 patients did not. Following drug discontinuation, plasma homovanillic acid concentrations were higher in schizophrenic patients who decompensated than in those who did not. Furthermore, peak plasma homovanillic acid elevation after discontinuation of neuroleptic medication was significantly correlated with peak Brief Psychiatric Rating Scale increase. The data suggest that, in some schizophrenic patients, symptomatic decompensation after discontinuation of neuroleptic treatment is associated with increases in dopamine turnover.



Author Affiliations

From the Department of Psychiatry, Mount Sinai Hospital/School of Medicine, Bronx (NY) Veterans Affairs Medical Center.


Footnotes

Accepted for publication June 24, 1990.

Reprint requests to Department of Psychiatry, Bronx Veterans Affairs Medical Center, Psychiatry Service (116A), 130 W Kingsbridge Rd, Bronx, NY 10468 (Dr Davidson).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neuroleptic Withdrawal in Schizophrenic Patients: A Review of the Literature
Gilbert et al.
Arch Gen Psychiatry 1995;52:173-188.
ABSTRACT  

Plasma Homovanillic Acid Levels in First-Episode Schizophrenia: Psychopathology and Treatment Response
Koreen et al.
Arch Gen Psychiatry 1994;51:132-138.
ABSTRACT  

Schizophrenia as a Brain Disease: The Dopamine Receptor Story
Seeman
Arch Neurol 1993;50:1093-1095.
ABSTRACT  

Effects of Neuroleptic Treatment on Symptoms of Schizophrenia and Plasma Homovanillic Acid Concentrations
Davidson et al.
Arch Gen Psychiatry 1991;48:910-913.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.